Marisa Wexler, MS,  senior science writer—

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Outcomes for Treating Brain Vessel Problems in Vascular EDS Assessed

Surgical treatments for brain blood vessel problems with vascular Ehlers-Danlos syndrome (EDS) are increasingly successful, but caution is needed because the procedures carry a high rate of complications that can be deadly, a new study shows. “Endovascular therapy [blood vessel-based surgery] in patients with vascular EDS can be performed efficaciously, with…

Use of Complementary, Alternative Medicines in hEDS Assessed

Many people with hypermobile Ehlers-Danlos syndrome (hEDS) have tried complementary and alternative medical (CAM) techniques like massage therapy or meditation and some report these help manage pain and other symptoms, according to a new study. “Our study shows that clinicians should be aware that many patients with chronic pain…

Small Nerve Fiber Dysfunction May Help Better Classify hEDS, HSD

Signs of dysfunction in small nerve fibers, the nerve cells mainly responsible for detecting sensations like pain, are found in people with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorder (HSD), according to a large retrospective study. Assessing these abnormalities could help better classify people with hEDS or HSD based…

Aytu Begins Phase 3 Trial of AR101, Possible Vascular EDS Treatment

Aytu BioPharma has launched a Phase 3 trial, called PREVEnt, to evaluate its experimental oral treatment AR101 (enzastaurin) in people with COL3A1-positive vascular Ehlers-Danlos Syndrome — vascular EDS or vEDS — a severe subtype of the disease. “We are excited about the progression of this global clinical trial evaluating…